ESMO | Prof. Lu Xie: B7-H3 ADC in Osteosarcoma—First Positive Phase III in 30 Years
Oncology | 27 OCT 2026 · MedJ ·
Prof. Lu Xie
Live from the Presidential Forum! Prof. Lu Xie presented the ARTEMIS-011 study: B7-H3 ADC in relapsed osteosarcoma achieved a PFS of 5.5 months, marking the first positive Phase III trial in nearly 30 years and filling a clinical unmet need.
0
0